For research use only
| Cat No. | ABC-TC5561 |
| Product Type | Human Lung Cancer Cell Lines |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Lung Adenocarinoma |
| Product Code | H322; H-322; H322T; NCI-H322T; NCIH322T; NCI-322; NCIH322 |
NCI-H322 lung carcinoma cells express SP-A, metabolize BaP, lack UGT, ideal for studying glutathione pathways, carcinogenesis,and tumor suppressor targets.
The NCI-H322 cell line is a well-characterized human non-small cell lung cancer (NSCLC) model derived from lung adenocarcinoma in a 52-year-old male patient, exhibiting epithelial morphology with Clara cell-like features (dense cytoplasmic granules, apical microvilli). These adherent cells retain tumorigenicity in immunodeficient mice, They demonstrate a distinct metabolic profile characterized by expression of surfactant protein A (SP-A), glutathione-S-transferase (GST), and phenol sulfotransferase (SULT). Genetically, they harbor a TP53 mutation and metabolize benzo(a)pyrene (BaP) into carcinogenic intermediates (e.g., 7, 8-diol-9, 10-epoxide-BaP), enabling studies of lung carcinogenesis pathways. Unlike many NSCLC models, NCI-H322 maintains wild-type EGFR, offering a distinct tool for targeted therapy research.
| Product Code | H322; H-322; H322T; NCI-H322T; NCIH322T; NCI-322; NCIH322 |
| Species | Human |
| Cat.No | ABC-TC5561 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Growth Mode | Adherent |
| Shipping Info | Dry ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Lung Adenocarinoma |
| Biosafety Level | 2 |
| Storage | Liquid Nitrogen |
| Product Type | Human Lung Cancer Cell Lines |
The NCI-H322 cell line is uniquely valuable for studying xenobiotic metabolism due to its deficient UDP-glucuronosyltransferase (UGT) activity, enabling focused investigation of toxins (e.g., benzo[a]pyrene) that rely on glucuronidation for detoxification. These cells are widely used to assess cytotoxicity, genotoxicity, and metabolic activation of carcinogens in human lung tissue, particularly for compounds where alternative Phase II pathways (e.g., GST-mediated) dominate. Additionally, their TP53-mutated, EGFR wild-type genotype makes them a relevant model for probing tumor suppressor mechanisms and evaluating targeted therapies, especially in p53-deficient lung adenocarcinoma contexts. The cell line’s tumorigenicity in murine xenografts further supports preclinical applications, including drug efficacy testing and biomarker discovery for NSCLC.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
NCI-H322 is a human non-small cell lung cancer (NSCLC) cell line used in cancer research.
NCI-H322 cells can be obtained from cell line repositories such as the AcceGen (ABC-TC5561 NCI-H322).
Use tissue culture-treated flasks or dishes to ensure proper cell adherence.
Check Culture Conditions: Ensure the temperature, CO₂ levels, and medium are appropriate.
Serum Concentration: Verify that the FBS concentration is at 10%.
Contamination Check: Inspect for contamination and treat or discard contaminated cultures.
Cell Viability: Consider using fresh cells or a new batch.
